Rocket Pharma secures credit facility for up to $150 million from Hercules Capital

PUBT · 2d ago
Rocket Pharma secures credit facility for up to $150 million from Hercules Capital
  • Rocket Pharmaceuticals entered a credit facility with Hercules Capital for up to $150 million to support its Danon disease program.
  • $35 million funded at closing; another $35 million available at Rocket’s option during specified periods under the agreement.
  • Additional $30 million tied to a Danon clinical milestone; extra $50 million subject to Hercules investment committee approval.
  • Facility includes a 30-month interest-only period; 48-month maturity with milestone-based extension options.
  • Rocket expects cash resources, including the initial draw, to fund operations into Q3 2028; further draws could extend runway into 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610061612BIZWIRE_USPR_____20261006_BW391991) on October 06, 2026, and is solely responsible for the information contained therein.